Chronic lymphocytic leukemia prognostic models in real life: still a long way off

Click to increase image sizeClick to decrease image size

Declaration of interest

S Molica has received advisory board honorarium from AbbVie, Jansen, and Astra Zeneca; he has also received speaker bureau honoraria from Gilead. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed here.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.